Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.37 |
| ▸ | PDE4A | P27815 | 4/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24632331 | 0.84 | AR (0.45) | ARNR3C1PGRSMN1; SMN2HSD17B10 | |
| SCHEMBL29665818 | 0.84 | AR (0.45) | ARNR3C1PGRSMN1; SMN2HSD17B10 | |
| SCHEMBL29316555 | 0.81 | AR (0.57) | ARPGRSMN1; SMN2HSD17B10S1PR1 | |
| SCHEMBL29316564 | 0.81 | AR (0.56) | ARPGR | |
| SCHEMBL29316588 | 0.78 | AR (0.66) | AR | |
| SCHEMBL29316534 | 0.78 | AR (0.53) | ARPGRSMN1; SMN2 | |
| SCHEMBL29316518 | 0.77 | AR (0.44) | ARPGRPDE4BPDE4DS1PR1 | |
| SCHEMBL27027444 | 0.77 | AR (0.44) | ARPGRS1PR1 | |
| SCHEMBL27027445 | 0.77 | AR (0.49) | ARPGRS1PR1 | |
| SCHEMBL29316540 | 0.75 | AR (0.43) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | AR 658/4885NR3C1 281/4885PGR 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.